Fusobacterium nucleatum inhibits human T-cell activation by arresting cells in the mid-G1 phase of the cell cycle - PubMed (original) (raw)
Fusobacterium nucleatum inhibits human T-cell activation by arresting cells in the mid-G1 phase of the cell cycle
B J Shenker et al. Infect Immun. 1995 Dec.
Abstract
Fusobacterium nucleatum has been implicated in the pathogenesis of several diseases, including urinary tract infections, bacteremia, pericarditis, otitis media, and disorders of the oral cavity such as pulpal infections, alveolar bone abscesses, and periodontal disease. We have previously demonstrated that sonic extracts of F. nucleatum FDC 364 were capable of inhibiting human T-cell responses to mitogens and antigens. In this study, we have further characterized this immunosuppressive protein (FIP) and initiated experiments to determine its mode of action. The purified FIP has an apparent molecular mass of 90 to 100 kDa; sodium dodecyl sulfate-polyacrylamide gel electrophoresis indicates that the FIP is actually composed of two subunits with molecular masses of 48 and 44 kDa. Purified FIP retained its biological activity and was capable of inhibiting mitogen-induced proliferation of human T cells. Inhibition was dose dependent, and the FIP exhibited a specific activity approximately 250-fold greater than that of the crude extract. Cell cycle analysis indicates that FIP-treated cells were prevented from exiting the G0/G1 phase of the cell cycle. However, FIP did not alter the expression of activation markers (CD69, CD25, and CD71) or interleukin-2 secretion. The latter observations suggest that the T cells did indeed become activated and had entered the G1 phase of the cell cycle. Analysis of the expression of cyclins indicates that the phase of the cell cycle that is FIP sensitive resides somewhere beyond the restriction point of cyclin D2 (early to mid-G1) but prior to that of cyclins D3 and E (mid- to late G1). Finally, analysis of the expression of the proliferating cell nuclear antigen indicates that this is the earliest detectable defect in T cells exposed to FIP. We propose that if a block in the G1 phase of the cell cycle occurs in vivo in lymphocytes, it may result in a state of local and/or systemic immunosuppression. These suppressive effects could alter the nature and consequences of host-parasite interactions, thereby enhancing the pathogenicity of F. nucleatum itself or that of some other opportunistic organisms.
Similar articles
- Suppression of human peripheral blood lymphocytes by Fusobacterium nucleatum.
Shenker BJ, DiRienzo JM. Shenker BJ, et al. J Immunol. 1984 May;132(5):2357-62. J Immunol. 1984. PMID: 6715883 - Identification and analysis of fipA, a Fusobacterium nucleatum immunosuppressive factor gene.
Demuth DR, Savary R, Golub E, Shenker BJ. Demuth DR, et al. Infect Immun. 1996 Apr;64(4):1335-41. doi: 10.1128/iai.64.4.1335-1341.1996. Infect Immun. 1996. PMID: 8606098 Free PMC article. - Treponema denticola immunoinhibitory protein induces irreversible G1 arrest in activated human lymphocytes.
Lee W, Pankoski L, Zekavat A, Shenker BJ. Lee W, et al. Oral Microbiol Immunol. 2004 Jun;19(3):144-9. doi: 10.1111/j.0902-0055.2004.00129.x. Oral Microbiol Immunol. 2004. PMID: 15107064 - Independent regulation of human D-type cyclin gene expression during G1 phase in primary human T lymphocytes.
Ajchenbaum F, Ando K, DeCaprio JA, Griffin JD. Ajchenbaum F, et al. J Biol Chem. 1993 Feb 25;268(6):4113-9. J Biol Chem. 1993. PMID: 8382693 - Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer.
Nosho K, Sukawa Y, Adachi Y, Ito M, Mitsuhashi K, Kurihara H, Kanno S, Yamamoto I, Ishigami K, Igarashi H, Maruyama R, Imai K, Yamamoto H, Shinomura Y. Nosho K, et al. World J Gastroenterol. 2016 Jan 14;22(2):557-66. doi: 10.3748/wjg.v22.i2.557. World J Gastroenterol. 2016. PMID: 26811607 Free PMC article. Review.
Cited by
- Fusobacterium nucleatum and colorectal cancer: From phenomenon to mechanism.
Ou S, Wang H, Tao Y, Luo K, Ye J, Ran S, Guan Z, Wang Y, Hu H, Huang R. Ou S, et al. Front Cell Infect Microbiol. 2022 Nov 29;12:1020583. doi: 10.3389/fcimb.2022.1020583. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 36523635 Free PMC article. Review. - Fusobacterium nucleatum: a novel immune modulator in breast cancer?
Little A, Tangney M, Tunney MM, Buckley NE. Little A, et al. Expert Rev Mol Med. 2023 Apr 3;25:e15. doi: 10.1017/erm.2023.9. Expert Rev Mol Med. 2023. PMID: 37009688 Free PMC article. Review. - Could Periodontal Disease through Periopathogen Fusobacterium Nucleatum be an Aggravating Factor for Gastric Cancer?
Șurlin P, Nicolae FM, Șurlin VM, Pătrașcu Ș, Ungureanu BS, Didilescu AC, Gheonea DI. Șurlin P, et al. J Clin Med. 2020 Nov 29;9(12):3885. doi: 10.3390/jcm9123885. J Clin Med. 2020. PMID: 33260439 Free PMC article. Review. - Fusobacterium and Colorectal Cancer.
Zhou Z, Chen J, Yao H, Hu H. Zhou Z, et al. Front Oncol. 2018 Oct 15;8:371. doi: 10.3389/fonc.2018.00371. eCollection 2018. Front Oncol. 2018. PMID: 30374420 Free PMC article. Review. - Identification and characterization of a novel adhesin unique to oral fusobacteria.
Han YW, Ikegami A, Rajanna C, Kawsar HI, Zhou Y, Li M, Sojar HT, Genco RJ, Kuramitsu HK, Deng CX. Han YW, et al. J Bacteriol. 2005 Aug;187(15):5330-40. doi: 10.1128/JB.187.15.5330-5340.2005. J Bacteriol. 2005. PMID: 16030227 Free PMC article.
References
- Am Fam Physician. 1981 Mar;23(3):201-4 - PubMed
- Scand J Dent Res. 1977 Jan-Feb;85(2):114-21 - PubMed
- J Clin Periodontol. 1987 Oct;14(9):489-98 - PubMed
- J Clin Microbiol. 1983 Feb;17(2):349-51 - PubMed
- Infect Immun. 1983 Jan;39(1):29-37 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials